Comparison of oral thrombin inhibitor and vitamin K antagonist in the treatment of acute venous thromboembolism:systematic review and meta-analysis
SUN Hu
ZHANG Ying
YE Yuan-zheng
ZUO Lei
Abstract：Objective To systematically evaluate the safety and efficacy of the new oral thrombin inhibitor and vitamin K antagonist in the treatment of acute venous thromboembolism, and to provide evidence for the choice of drugs for acute venous thromboembolism.Methods A Randomized Controlled Trials (RCT) study of the efficacy and safety of oral thrombin inhibitors and vitamin K antagonists in patients with acute venous thromboembolism was searched for by PubMed, EMbase, The Cochrane Library, WanFang Data, CBM and CNKI. The retrieval time limit is defined as building the library to March 2016. Meta-analysis was performed using RevMan 5.3 software for each outcome.Results A total of 7 RCTs involving 29932 patients were included. The results of meta-analysis showed that: There is no significant difference of effect between oral thrombin inhibitor group and vitamin K antagonist group [OR=0.93, 95%CI (0.81, 1.06),P=0.28]. The incidence of major bleeding in the new thrombin inhibitor group was significantly lower than that in the vitamin K antagonist group [OR=0.61, 95%CI (0.50, 0.75), P<0.00001].Conclusion New thrombin inhibitors can provide a better therapeutic effect for patients with acute venous thromboembolism, and its safety is also higher. But its safety and efficacy of treatment in domestic patients with acute venous thromboembolism still need to be verified in domestic RCTs with more samples.
Keywords：New oral thrombin inhibitorVitamin K antagonistAcute venous thromboembolismSystematic review
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 14-18 )